Home › All Companies › ARDX

ARDELYX, INC. (ARDX)

AI-Powered SEC Filing Analysis

Current Report Filed: 2026-04-30

Key Insights

  • Ardelyx announced Q1 2026 financial results on April 30, 2026, indicating the company is actively reporting operational performance to investors through standard earnings disclosure procedures.
  • The company hosted a conference call with an earnings presentation (Exhibit 99.2) to discuss Q1 2026 results, suggesting management engagement with investors and analysts regarding business performance and strategy.
  • The filing was signed by Susan Hohenleitner, Chief Financial Officer, indicating proper corporate governance and authorization of financial disclosures.
Sentiment: Neutral Significance: 3/10
View Original Filing →
Quarterly Report Filed: 2026-04-30

Key Insights

  • The filing contains multiple revenue segments including product sales (IBSRELA, XPHOZAH), product supply revenue, and license revenue, indicating a diversified revenue model across pharmaceutical products and partnerships.
  • The company maintains investments in multiple asset classes including money market funds, US Treasury securities, commercial paper, and corporate debt securities, suggesting conservative cash management and liquidity preservation strategies.
  • Detailed fair value measurement disclosures across Level 1, 2, and 3 inputs for various investment securities indicate active portfolio management and potential exposure to market valuation changes.
  • The presence of royalty-related transactions suggests revenue from intellectual property monetization or product licensing arrangements that may provide ongoing non-product revenue streams.
Sentiment: Neutral Significance: 4/10
View Original Filing →
Insider Trading Filed: 2026-04-17

Key Insights

  • Insider Michael Raab, the President and CEO of Ardelyx, Inc., has exercised 20,834 stock options and sold 41,668 shares of the company's common stock.
  • The shares were sold at a weighted average price of $6.2867, indicating that Raab is likely monetizing some of his equity holdings.
  • Raab still holds a significant stake in the company, directly owning 1,795,614 shares and indirectly owning an additional 25,364 shares through family trusts.
Sentiment: Neutral Significance: 4/10
View Original Filing →
Insider Trading Filed: 2026-03-18

Key Insights

  • The reporting person, Michael Raab, exercised 20,833 stock options and immediately sold 41,666 shares of common stock, suggesting he is liquidating a portion of his equity holdings in the company.
  • Raab still holds a significant stake in the company, directly owning over 1.8 million shares and indirectly owning an additional 25,364 shares through family trusts.
  • The stock option exercise and sale were executed pursuant to a 10b5-1 trading plan, indicating the transactions were pre-planned and not based on any inside information.
Sentiment: Neutral Significance: 4/10
View Original Filing →
Insider Trading Filed: 2026-01-27

Key Insights

  • Joseph James Reilly, the Senior Vice President of Finance at Ardelyx, Inc. (ARDX), acquired 46,200 shares of the company's common stock at $0 per share through the vesting of restricted stock units (RSUs).
  • Reilly now holds a total of 156,781 shares of Ardelyx, Inc. common stock, both directly and indirectly, indicating an increase in his ownership stake.
  • Reilly also received an option to purchase 69,360 shares of Ardelyx, Inc. common stock at an exercise price of $7.77 per share, with the option vesting in 48 equal monthly installments over the next three years.
Sentiment: Positive Significance: 6/10
View Original Filing →
Insider Trading Filed: 2026-01-26

Key Insights

  • John E. Bishop, the Chief Technical and Quality Officer, acquired 124,330 restricted stock units (RSUs) and received an option to purchase 186,500 shares of common stock at an exercise price of $7.77. This indicates that the company is incentivizing its key executive with equity-based compensation, potentially aligning his interests with those of shareholders.
  • The vesting schedule for the stock option indicates that it will vest in 48 equal monthly installments, subject to Bishop's continued employment or service relationship with the company. This gradual vesting schedule helps to retain the executive and ensure long-term alignment.
  • The significant size of the equity grants, both in terms of the number of RSUs and the stock option, suggests that Bishop is a key contributor to the company and that the board of directors believes in his ability to drive the company's success.
Sentiment: Positive Significance: 7/10
View Original Filing →
Insider Trading Filed: 2026-01-26

Key Insights

  • The reporting person, Laura A. Williams, has acquired 82,695 restricted stock units (RSUs) and a stock option to purchase 124,040 shares of the company's common stock, indicating management's confidence in the company's future.
  • The vesting schedule of the stock option, with shares vesting in 48 equal monthly installments, suggests a long-term commitment to the company's success.
  • The insider transaction suggests management is aligning their interests with shareholders, which could be viewed positively by investors.
Sentiment: Positive Significance: 7/10
View Original Filing →
Insider Trading Filed: 2026-01-26

Key Insights

  • James Parker Brady, the Chief Human Resources Officer of Ardelyx, Inc., has acquired 99,455 shares of the company's common stock through restricted stock units, increasing his total direct beneficial ownership to 265,455 shares.
  • Brady has also been granted a stock option to purchase 149,185 shares of Ardelyx's common stock, with the option vesting in monthly installments over the next 3 years.
  • The significant insider buying activity suggests that Brady, a key executive, is confident in Ardelyx's future prospects and aligns his interests with those of shareholders.
Sentiment: Positive Significance: 7/10
View Original Filing →
Insider Trading Filed: 2026-01-26

Key Insights

  • Insider Michael Raab, the President and CEO of Ardelyx, acquired a significant number of 669,330 stock options and 446,220 restricted stock units, indicating his confidence in the company's future prospects.
  • Raab also holds additional shares in Ardelyx through a family trust, suggesting his alignment with long-term shareholder interests.
  • The large equity awards to the CEO, granted at an exercise price of $7.77, provide strong incentives for him to drive the company's growth and performance in the coming years.
Sentiment: Positive Significance: 7/10
View Original Filing →
Insider Trading Filed: 2026-01-26

Key Insights

  • Eric D. Foster, the Chief Commercial Officer of Ardelyx, Inc., has acquired 137,945 restricted stock units (RSUs) on January 23, 2026, indicating his confidence in the company's future prospects.
  • Foster has also been granted 206,915 stock options, which vest over a 4-year period, further aligning his interests with those of Ardelyx shareholders.
  • The insider buying activity, combined with the vesting schedule of the stock options, suggests that Foster believes in the long-term growth potential of Ardelyx's business.
Sentiment: Positive Significance: 7/10
View Original Filing →
Insider Trading Filed: 2026-01-26

Key Insights

  • The reporting person, Susan Hohenleitner, acquired 85,670 restricted stock units (RSUs) and 128,505 stock options, indicating potential insider confidence in the company's future performance.
  • The acquisition of a substantial number of equity securities suggests that Hohenleitner, as the Chief Financial Officer, believes in the company's growth prospects and aligns her interests with those of shareholders.
  • The vesting schedule of the stock options, with 48 equal monthly installments, suggests a long-term commitment to the company and a focus on sustained performance over time.
Sentiment: Positive Significance: 7/10
View Original Filing →
Insider Trading Filed: 2026-01-26

Key Insights

  • The reporting person, Mike Kelliher, was granted 103,080 restricted stock units (RSUs) and 154,625 stock options, indicating potential insider buying and alignment of interests with shareholders.
  • The stock options vest over 48 months, suggesting a long-term commitment and confidence in the company's future performance.
  • The significant number of equity awards, valued at over $2 million based on the current stock price, signals the company's efforts to incentivize and retain key leadership.
Sentiment: Positive Significance: 7/10
View Original Filing →
Current Report Filed: 2026-01-08

Key Insights

  • Ardelyx reported strong net product sales for IBSRELA ($87 million in Q4 2025, $274 million for full year 2025) and XPHOZAH ($28 million in Q4 2025, $104 million for full year 2025), indicating successful commercialization of its key products.
  • The company had a healthy cash, cash equivalents, and short-term investments balance of approximately $265 million as of December 31, 2025, suggesting financial stability and the ability to fund ongoing operations.
  • The preliminary financial data provided is unaudited, so investors should await the company's audited financial statements for the full year 2025 to get a complete picture of the financial performance.
Sentiment: Positive Significance: 7/10
View Original Filing →

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.